(0.09%) 5 521.75 points
(0.14%) 39 898 points
(0.19%) 19 788 points
(-0.01%) $81.62
(0.53%) $2.83
(-0.28%) $2 337.80
(0.17%) $29.58
(0.30%) $1 004.80
(0.00%) $0.931
(-0.03%) $10.53
(-0.01%) $0.788
(-0.84%) $87.25
1.46% $ 6.25
Live Chart Being Loaded With Signals
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 3.59M |
Średni wolumen | 4.92M |
Kapitalizacja rynkowa | 1.46B |
EPS | $-0.110 ( Q1 | 2024-05-02 ) |
Następna data zysków | ( $0 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-22.32 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0120 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-14 | Rodgers Richard J | Buy | 12 204 | Common Stock |
2024-06-14 | Rodgers Richard J | Buy | 40 243 | Stock Option (Right to Buy) |
2024-06-14 | Bhanji Muna | Buy | 40 243 | Stock Option (Right to Buy) |
2024-06-14 | Bertrand William C Jr | Buy | 11 023 | Common Stock |
2024-06-14 | Bertrand William C Jr | Buy | 40 243 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
31.97 |
Last 99 transactions |
Buy: 4 302 816 | Sell: 2 049 265 |
Wolumen Korelacja
Ardelyx Inc Korelacja
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ardelyx Inc Korelacja - Waluta/Towar
Ardelyx Inc Finanse
Annual | 2023 |
Przychody: | $124.46M |
Zysk brutto: | $106.66M (85.70 %) |
EPS: | $-0.300 |
FY | 2023 |
Przychody: | $124.46M |
Zysk brutto: | $106.66M (85.70 %) |
EPS: | $-0.300 |
FY | 2022 |
Przychody: | $52.16M |
Zysk brutto: | $48.04M (92.11 %) |
EPS: | $-0.420 |
FY | 2021 |
Przychody: | $10.10M |
Zysk brutto: | $9.10M (90.10 %) |
EPS: | $-1.520 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej